RZLT Rezolute Inc
Company Analysis
Latest News
🟢 Rezolute is trading 13.38% up in pre-market with biotech strength; company-specific catalyst remains unclear
Rezolute is trading at $4.49, up +13.38% in pre-market, with biotech-sector strength offering context; no confirmed company-specific overnight catalyst...
Rezolute Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Rezolute Inc is expected to report a consensus EPS of -$0.18 on revenue of $1.12 million for the quarter ending September 30, 2026, with its current $4.01...
🟢 Rezolute is trading 6% up — cause remains unclear
Rezolute is trading 5.80% up at $4.11, with no clear catalyst identified for the November 3 move. - The November 2 announcement about upcoming investor...
🟢 Rezolute is trading 7% up in pre-market
Rezolute is trading 6.96% higher at $4.15 in pre-market on November 3, compared with its November 2 close of $3.88. No clear overnight company-specific...
🔴 Rezolute is trading 5% down
Rezolute is trading 5.06% lower at $3.75; biotech sector weakness is the strongest available context, but the cause remains uncertain. - Biotech stocks are...
Rezolute Highlights Ersodetug Clinical Progress and Positive FDA Feedback
Rezolute (RZLT) released an investor presentation providing a comprehensive update on its late-stage clinical programs for its lead candidate, ersodetug, for...
🟢 Rezolute is trading 5.8% up with no clear company-specific catalyst
Rezolute is trading up 5.76% at $4.04 on October 27, 2026; no new company-specific announcement was found to explain the move. - On October 14, Rezolute...
🟢 Rezolute is trading 5% up
Rezolute is trading 5.41% higher at $3.90 on October 22, 2026, diverging from broad market declines; no clear company-specific announcement or confirmed...
🔴 Rezolute is trading 5% down on October 19
Rezolute is trading at $3.40, down 5.03%, after four consecutive declining closes; no clear company-specific announcement was identified on October 19 to...
🔴 Rezolute is trading 7.2% down today as biotech weakness may contribute
Rezolute is trading 7.18% down at $3.62 after several consecutive sessions of declines, with biotech-sector weakness potentially contributing. - No clear...
🔴 Rezolute is trading 5% down with no clear catalyst identified
Rezolute is trading 5.08% down now at $4.01, with no reliable report linking the decline to a new company event. - The price context shows a further decline...
Rezolute Completes Phase 3 Enrollment for Tumor Hyperinsulinism Drug, Topline Data Expected Dec 2026
Rezolute, Inc. announced it has completed patient enrollment for its pivotal Phase 3 registrational study, upLIFT, evaluating its drug candidate ersodetug for...
🟢 Rezolute is trading 6.6% up in after-hours trading after announcing full Phase 3 upLIFT enrollment
Rezolute is trading at $4.51, up 6.62%, after-hours following its announcement that the Phase 3 upLIFT study of ersodetug is fully enrolled. - The company...
🔴 Rezolute is trading 5% down on October 14, 2026, with no clear company-specific catalyst identified
Rezolute is trading at $4.37 (-5.21%) in live trading, with broader risk-off pressure a possible backdrop—not an established cause. - No new Rezolute...
🔴 Rezolute is trading 5% down
Rezolute is trading 5.24% down at $4.62, with no clear company-specific announcement identified to explain the October 13 decline. - Biotech was down 2.01%,...
🟢 Rezolute is trading 5% up today
Rezolute is trading at $4.89 (+5.38%) on October 9, amid biotech-sector strength; no direct cause of the move was confirmed. - XBI was reported up 2.50% during...
🟢 Rezolute is trading 5% up today
Rezolute is trading at $4.61, up 5.25% in live trading on October 8, 2026; no clear company-specific catalyst has been identified. - Rezolute’s...
🔴 Rezolute is trading 10% down in pre-market
Rezolute is trading 10.09% lower at $3.94 in pre-market, with no clearly reported company-specific announcement on October 8, 2026, explaining the decline. -...
🟢 Rezolute is trading 5% up today after FDA recommended an ersodetug pre-BLA meeting
Rezolute is trading 5.21% up at $4.54 after the FDA recommended that the company request a pre-BLA meeting for ersodetug. - The recommendation followed the...
🟢 Rezolute is trading 7% up in pre-market after FDA recommended a pre-BLA meeting
Rezolute is trading at $4.63, up 6.99% in pre-market after the FDA recommended a pre-BLA meeting for ersodetug on October 5, following its review of sunRIZE...